These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 19561408)

  • 1. Reduced-intensity conditioning allogeneic stem cell transplantation with donor T-cell depletion using alemtuzumab added to the graft ('Campath in the bag').
    von dem Borne PA; Starrenburg CW; Halkes SJ; Marijt WA; Fibbe WE; Falkenburg JH; Willemze R
    Curr Opin Oncol; 2009 Jun; 21 Suppl 1():S27-9. PubMed ID: 19561408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term follow-up of myeloablative allogeneic stem cell transplantation using Campath "in the bag" as T-cell depletion: the Leiden experience.
    Barge RM; Starrenburg CW; Falkenburg JH; Fibbe WE; Marijt EW; Willemze R
    Bone Marrow Transplant; 2006 Jun; 37(12):1129-34. PubMed ID: 16757974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategy.
    Shore T; Harpel J; Schuster MW; Roboz GJ; Leonard JP; Coleman M; Feldman EJ; Silver RT
    Biol Blood Marrow Transplant; 2006 Aug; 12(8):868-75. PubMed ID: 16864057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of in vivo T cell depletion with alemtuzumab on reduced-intensity allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia.
    Delgado J; Pillai S; Benjamin R; Caballero D; Martino R; Nathwani A; Lovell R; Thomson K; Perez-Simon JA; Sureda A; Kottaridis P; Vazquez L; Peggs K; Sierra J; Milligan D; Mackinnon S
    Biol Blood Marrow Transplant; 2008 Nov; 14(11):1288-97. PubMed ID: 18940684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of graft vs. host disease with alemtuzumab 'in the bag' decreases early toxicity of stem cell transplantation and in multiple myeloma is associated with improved long-term outcome.
    Novitzky N; Thomas V; du Toit C
    Cytotherapy; 2008; 10(1):45-53. PubMed ID: 18202974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
    Hale G; Slavin S; Goldman JM; Mackinnon S; Giralt S; Waldmann H
    Bone Marrow Transplant; 2002 Dec; 30(12):797-804. PubMed ID: 12476271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes.
    Peggs KS; Sureda A; Qian W; Caballero D; Hunter A; Urbano-Ispizua A; Cavet J; Ribera JM; Parker A; Canales M; Mahendra P; Garcia-Conde J; Milligan D; Sanz G; Thomson K; Arranz R; Goldstone AH; Alvarez I; Linch DC; Sierra J; Mackinnon S;
    Br J Haematol; 2007 Oct; 139(1):70-80. PubMed ID: 17854309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post-transplant T cell chimerism predicts graft versus host disease but not disease relapse in patients undergoing an alemtuzumab based reduced intensity conditioned allogeneic transplant.
    Nikolousis E; Robinson S; Nagra S; Brookes C; Kinsella F; Tauro S; Jeffries S; Griffiths M; Mahendra P; Cook M; Paneesha S; Lovell R; Kishore B; Chaganti S; Malladi R; Raghavan M; Moss P; Milligan D; Craddock C
    Leuk Res; 2013 May; 37(5):561-5. PubMed ID: 23395505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced-intensity conditioning containing low-dose alemtuzumab before allogeneic peripheral blood stem cell transplantation: graft-versus-host disease is decreased but T-cell reconstitution is delayed.
    Dodero A; Carrabba M; Milani R; Rizzo E; Raganato A; Montefusco V; Farina L; Milanesi M; Longoni P; Carlo-Stella C; Corradini P
    Exp Hematol; 2005 Aug; 33(8):920-7. PubMed ID: 16038785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In stem cell transplantation, by limiting the morbidity of graft-versus-host disease tolerance to myeloablative conditioning is improved.
    Novitzky N; Thomas V; du Toit C; Mcdonald A
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):709-18. PubMed ID: 18489997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Partial T cell-depleted allogeneic stem cell transplantation following reduced-intensity conditioning creates a platform for immunotherapy with donor lymphocyte infusion and recipient dendritic cell vaccination in multiple myeloma.
    Levenga H; Schaap N; Maas F; Esendam B; Fredrix H; Greupink-Draaisma A; de Witte T; Dolstra H; Raymakers R
    Biol Blood Marrow Transplant; 2010 Mar; 16(3):320-32. PubMed ID: 19835972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose alemtuzumab vs. standard policy for prevention of graft-versus-host disease in unrelated and related allogeneic stem cell transplantation-a matched pair analysis.
    Busemann C; Neumann T; Schulze M; Klenner A; Thiele T; Greinacher A; Dölken G; Krüger WH
    Ann Hematol; 2013 Jul; 92(7):945-52. PubMed ID: 23463451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of alemtuzumab in nonmyeloablative hematopoietic transplantation.
    Giralt S
    Semin Oncol; 2006 Apr; 33(2 Suppl 5):S36-43. PubMed ID: 16720202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes after myeloablative unrelated donor stem cell transplantation using both in vitro and in vivo T-cell depletion with alemtuzumab.
    von dem Borne PA; Beaumont F; Starrenburg CW; Oudshoorn M; Hale G; Falkenburg JH; Fibbe WE; Willemze R; Barge RM
    Haematologica; 2006 Nov; 91(11):1559-62. PubMed ID: 17082014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose alemtuzumab (Campath) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies: decreased incidence of acute graft-versus-host-disease with unique pharmacokinetics.
    Khouri IF; Albitar M; Saliba RM; Ippoliti C; Ma YC; Keating MJ; Champlin RE
    Bone Marrow Transplant; 2004 Apr; 33(8):833-7. PubMed ID: 14755312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of Campath and Thymoglobulin as part of the conditioning before allogeneic hematopoietic stem cell transplantation.
    Norlin AC; Remberger M
    Eur J Haematol; 2011 Jan; 86(1):57-66. PubMed ID: 20942840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Campath-1 Abs 'in the bag' for hematological malignancies: the Cape Town experience.
    Novitzky N; Thomas V; Hale G; Waldmann H
    Cytotherapy; 2004; 6(2):172-81. PubMed ID: 15203994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minimal GVHD following in-vitro T cell-depleted allogeneic stem cell transplantation with reduced-intensity conditioning allowing subsequent infusions of donor lymphocytes in patients with hematological malignancies and solid tumors.
    Barge RM; Osanto S; Marijt WA; Starrenburg CW; Fibbe WE; Nortier JW; Falkenburg JH; Willemze R
    Exp Hematol; 2003 Oct; 31(10):865-72. PubMed ID: 14550801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute GVHD is a strong predictor of full donor CD3+ T cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation.
    El-Cheikh J; Vazquez A; Crocchiolo R; Furst S; Calmels B; Castagna L; Lemarie C; Granata A; Ladaique P; Oudin C; Faucher C; Chabannon C; Blaise D
    Am J Hematol; 2012 Dec; 87(12):1074-8. PubMed ID: 22911907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.